Understand the source comparison
Dihexa Versus Other Neuroplasticity-Targeting Compounds
Understanding where dihexa fits within the landscape of neuroplasticity-promoting agents requires comparing it not just to endogenous growth factors but to other research compounds targeting overlapping pathways. The table below distills the key pharmacologica
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding where dihexa fits within the landscape of neuroplasticity-promoting agents requires comparing it not just to endogenous growth factors but to other research compounds targeting overlapping pathways. The table below distills the key pharmacological and practical distinctions.
- Dihexa
- Direct c-Met receptor agonist
- High. Small peptide, crosses via passive diffusion
- ~7,000,000× more potent than BDNF in neurite outgrowth assays
- Cognitive enhancement, synaptic density studies, neurodegeneration models
- Most potent small-molecule c-Met agonist; narrow dose window requires precision
- BDNF (recombinant)
- TrkB receptor agonist
- None. 27 kDa protein, does not cross intact BBB
- 1× (reference standard)
- In vitro neuronal survival, differentiation protocols, ex vivo slice studies
- Gold standard for neurotrophin research but limited to non-systemic applications
- NSI-189
- Hippocampal neurogenesis stimulator (mechanism partially characterized)
- Moderate. Small molecule, but CNS exposure data limited
- Not directly comparable. Acts on progenitor cells, not mature synapses
- Depression models, hippocampal volume studies, neurogenesis quantification
- Targets different stage of plasticity (proliferation vs. synapse remodeling)
- Cerebrolysin
- Peptide mixture mimicking neurotrophic factors (BDNF, NGF, CNTF)
- Low. Large peptides, requires direct CNS delivery or high doses
- Variable. Contains multiple active components
- Stroke recovery, TBI models, neuroprotection studies
- Broad-spectrum but less selective; difficult to isolate mechanism of action
- P21
- DYRK1A inhibitor; indirect effects on CREB and synaptic gene transcription
- High. 24-amino-acid peptide derived from CNTF
- Not directly comparable. Modulates transcription, not receptor activation
- Memory consolidation, learning models, age-related cognitive decline
- Complements dihexa by targeting transcriptional phase rather than receptor phase
- The distinction between dihexa and compounds like Cerebrolysin or P21 is not one of superiority but of selectivity. Dihexa activates a single, well-characterized receptor system with dose-dependent kinetics that can be monitored via phosphorylation assays, neurite outgrowth quantification, and spine density imaging. Cerebrolysin and P21 work through broader or multi-target mechanisms that may be advantageous in certain models but complicate mechanistic attribution. For researchers prioritizing pathway-specific interrogation, dihexa HGF/c-Met pathway activation offers the clearest signal-to-noise ratio.